Drug Discovery & Pharmaceuticals

RSS

Oral drug that reverses immune aging effectively prevents death in COVID-19 mouse model

The immune system deteriorates with age, making COVID-19 particularly deadly in older people -; but to date, no clinically available medication addresses this key risk factor.

21 Mar 2022

Texas Biomed and UAB partnership uncovers a new, potent antibody cocktail against all coronaviruses

As SARS-CoV-2 has continued to evolve and outsmart existing treatments, scientists have not let up looking for ever-more effective tools to keep people safe and successfully recover from COVID-19, and to prepare for future outbreaks.

18 Mar 2022

Two clever human antibodies can target Ebola and Sudan virus

Researchers at La Jolla Institute for Immunology (LJI) are designing better therapies for treating Ebola virus and its deadly relatives.

17 Mar 2022

Sneaking large drug-carrying biological molecules into cells using a novel drug delivery system

Scientists from Nanyang Technological University, Singapore have developed a novel method of delivering drugs into human cells using large biological molecules, by first encasing them in a protein-based microdroplet.

16 Mar 2022

Ethyl lauroyl arginine hydrochloride (ELAH) nasal spray as potent antiviral against SARS-CoV-2

Researchers evaluate the virucidal effects of ELAH against SARS-CoV-2 and human coronavirus-229E in a nasal spray formulation.

15 Mar 2022

Acacetin shows potency against SARS-CoV-2 spike protein

Researchers use molecular docking to screen phytocompounds and evaluate their binding affinity with SARS-CoV-2.

15 Mar 2022

In silico screening of natural ACE2 inhibitors

Researchers identify potential ACE2 inhibitors through a virtual screening protocol.

14 Mar 2022

Three new drug companies join the COVIDRIVE consortium to study vaccine effectiveness

Three new drug companies (Moderna, Novavax and Valneva) have joined the COVIDRIVE consortium, becoming partners of this project coordinated by the Vaccine Research Department of the Foundation for the Promotion of Health and Biomedical Research of Valencia Region (Fisabio), an affiliate of the Conselleria de Sanitat Universal i Salut Pública, along with the company specialized in pharmacovigilance and epidemiology, P95.

8 Mar 2022

New analysis method to identify interacting proteins in a protein degrader-dependent manner

Protein degraders, which induce the protein degradation of target proteins, are expected to be the "next-generation drugs" because they can remove disease-related proteins from cells.

8 Mar 2022

A promising approach for COVID-19 prophylaxis

SARS-CoV-2 viruses can hide from recognition by the immune system. However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections.

8 Mar 2022

Current and future perspectives of mRNA technology

New research reports on the current and future perspectives on messenger ribonucleic acid technology, the platform on which the first successful COVID-19 vaccine was based.

8 Mar 2022

Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies

Orbit Discovery is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services.

8 Mar 2022

Study reveals the potential of novel antiviral drug combinations to stop COVID-19 spread

Researchers from Columbia Engineering, Fiocruz's Center for Technological Development in Health and the Oswaldo Cruz Institute in Brazil, Memorial Sloan Kettering Cancer Center, and Rockefeller University recently reported that, by combining inhibitors of polymerases and exonucleases--enzymes that allow SARS-CoV-2 to reproduce--they were able to reduce SARS-CoV-2 replication 10 times more than when using just the polymerase inhibitors.

7 Mar 2022

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Researchers develop an Omicron variant mRNA vaccine that is be more potent in generating nAbs as compared to other available vaccines.

6 Mar 2022

COVID-19 and the life sciences; what have we learned and where are we going?

News-Medical attended the 2022 SLAS press briefing where Peter Simpson, Michael Girardi, and Simon Meffan-Main gave their thoughts on the life sciences sector post-COVID-19.

From Society for Laboratory Automation and Screening (SLAS) 4 Mar 2022

Texas A&M team continues research on the potential cure for Menkes disease

A life-saving cure solution for Menkes Disease, a copper deficiency in young children, is at the center of a licensing agreement by the The Texas A&M University System, through the Intellectual Property and Commercialization office of Texas A&M AgriLife Research, and a California-based biopharmaceutical company, Engrail Therapeutics.

3 Mar 2022

Drug Discovery & Pharmaceuticals

Oral drug that reverses immune aging effectively prevents death in COVID-19 mouse model

Texas Biomed and UAB partnership uncovers a new, potent antibody cocktail against all coronaviruses

Two clever human antibodies can target Ebola and Sudan virus

Sneaking large drug-carrying biological molecules into cells using a novel drug delivery system

Ethyl lauroyl arginine hydrochloride (ELAH) nasal spray as potent antiviral against SARS-CoV-2

Acacetin shows potency against SARS-CoV-2 spike protein

In silico screening of natural ACE2 inhibitors

Three new drug companies join the COVIDRIVE consortium to study vaccine effectiveness

New analysis method to identify interacting proteins in a protein degrader-dependent manner

A promising approach for COVID-19 prophylaxis

Current and future perspectives of mRNA technology

Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies

Study reveals the potential of novel antiviral drug combinations to stop COVID-19 spread

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

COVID-19 and the life sciences; what have we learned and where are we going?

Texas A&M team continues research on the potential cure for Menkes disease

8G3 broad-spectrum antibody effective against all SARS-CoV-2 variants, including Omicron

UH researcher receives $2 million to develop drugs for traditionally undruggable targets in cancer

Adenosine receptor agonists provide therapeutic target in mouse SARS-CoV-2 infection

Optibrium Adds Augmented Intelligence for Compound Design to its StarDrop Small Molecule Drug Discovery Software

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest Life Science News